The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Open accessAbstract
Our understanding of Alzheimer's disease pathogenesis is currently limited by difficulties in obtaining live neurons from patients and the inability to model the sporadic form of the disease. It may be possible to overcome these challenges by reprogramming primary cells from patients into induced pluripotent stem cells (iPSCs). Here we reprogrammed primary fibroblasts from two patients with familial Alzheimer's disease, both caused by a duplication of the amyloid-β precursor protein gene (APP; termed APP(Dp)), two with sporadic Alzheimer's disease (termed sAD1, sAD2) and two non-demented control individuals into iPSC lines. Neurons from differentiated cultures were purified with fluorescence-activated cell sorting and characterized. Purified cultures contained more than 90% neurons, clustered with fetal brain messenger RNA samples by microarray criteria, and could form functional synaptic contacts. Virtually all cells exhibited normal electrophysiological activity. Relative to controls, iPSC-derived, purified neurons from the two APP(Dp) patients and patient sAD2 exhibited significantly higher levels of the pathological markers amyloid-β(1-40), phospho-tau(Thr 231) and active glycogen synthase kinase-3β (aGSK-3β). Neurons from APP(Dp) and sAD2 patients also accumulated large RAB5-positive early endosomes compared to controls. Treatment of purified neurons with β-secretase inhibitors, but not γ-secretase inhibitors, caused significant reductions in phospho-Tau(Thr 231) and aGSK-3β levels. These results suggest a direct relationship between APP proteolytic processing, but not amyloid-β, in GSK-3β activation and tau phosphorylation in human neurons. Additionally, we observed that neurons with the genome of one sAD patient exhibited the phenotypes seen in familial Alzheimer's disease samples. More generally, we demonstrate that iPSC technology can be used to observe phenotypes relevant to Alzheimer's disease, even though it can take decades for overt disease to manifest in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“iPSC-derived neurons from individuals with AD exhibit increased production of Aβ42, active GSK-3β, phosphorylated tau, endosomal abnormalities, and oxidative stress (12–17)”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“but late-stage neuropathological features, such as formation of insoluble tau and neurodegeneration have not been reported.”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accumulation of pTau in FAD neurons can be reversed by inhibition of β-secretase, the enzyme that converts APP to β-CTF indicating a direct relationship between APP processing and Tau (Israel et al., 2012, Moore et al., 2015).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points (Choi et al., 2014, Israel et al., 2012, Moore et al., 2015, Muratore et al., 2014, Ochalek et al., 2017, Shi et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, neuronal endosomal swelling has been classed as an early hallmark of Alzheimer's disease indicative of a perturbation in endosomal cargo sorting [8,9,56].”
From Global identification of neuronal and astrocytic integral membrane proteins that require Retromer for their endosomal recycling (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, inhibition of γ-secretase (to prevent generation of Aβ from β-CTF) did not reduce pTau, indicating that the effect of APP processing on pTau in early AD neurons is not solely mediated by extracellular Aβ (Israel et al., 2012, Moore et al., 2015).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“pThr231Tau accumulates in APP duplication (APPdp) iPSC-derived FAD neurons (Israel et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
In the citing paper
“Several studies related to neurological disease successfully reverted a disease-associated cellular phenotype in patient-derived cells by correcting the disease-associated mutation, for example in the MAPT gene106,107.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [106]
In the citing paper
“Multiple groups have characterized iPSC lines from donor cells from FAD and sAD patients, which show increased production of Aβ, particularly Aβ42, and tau hyperphosphorylation in comparison to iPSCs derived from age-matched non-demented controls [66, 82, 101, 175].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [66]
In the citing paper
“Some iPSC lines also have evidence of additional AD-associated pathology such as increased activation of GSK3β [66], increased number of large endosomes [66], and accumulation of intraneuronal Aβ oligomers [82].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liang, Q., Fujita, R., Yamashita, T., Angulo, S. L., Rhinn, H., Rhee, D. B., Doege, C. A., Chau, L., Aubry, L., Vanti, W. B., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.007 · Cited by 231
RetractedInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
Cited by
Sorted by citations
Items 401–500 of 1,002
Modeling Alzheimer’s Disease by Induced Pluripotent Stem Cells Carrying APP D678H Mutation
Chang, K., Lee‐Chen, G., Huang, C.-C., Lin, J.-L., Chen, Y.-J., Wei, P.-C., Lo, Y., Yao, C.-F., Kuo, M., & Chen, C. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1336-x · Cited by 42
Marzano, M., Bejoy, J., Cheerathodi, M. R., Sun, L. J., York, S. B., Zhao, J., Kanekiyo, T., Bu, G., Meckes, D. G., & Li, Y. (2019) · Cells · doi:10.3390/cells8090993 · Cited by 41
BrainPhys neuronal medium optimized for imaging and optogenetics in vitro
Zabolocki, M., McCormack, K., van den Hurk, M., Milky, B., Shoubridge, A. P., Adams, R., Tran, J., Mahadevan-Jansen, A. M., Reineck, P., Thomas, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19275-x · Cited by 45
Self-citationStem Cell Therapies in Alzheimer’s Disease: Applications for Disease Modeling
Si, Z., & Wang, X. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000324 · Cited by 42
Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models
Trombetta-Lima, M., Sabogal-Guáqueta, A. M., & Dolga, A. M. (2021) · Cell Calcium · doi:10.1016/j.ceca.2021.102362 · Cited by 42
Applications of induced pluripotent stem cells in studying the neurodegenerative diseases
Wan, W., Cao, L., Kalionis, B., Xia, S., & Tai, X. (2015) · Stem Cells International · doi:10.1155/2015/382530 · Cited by 40
CRISPR-based functional genomics screening in human-pluripotent-stem-cell-derived cell types
Li, K., Ouyang, M., Zhan, J., & Tian, R. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100300 · Cited by 45
γ-Secretase Modulator in Alzheimer's Disease: Shifting the End
Xia, W., Wong, S. T. C., Hanlon, E. B., & Morin, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120751 · Cited by 40
Alzheimer's disease research and development: a call for a new research roadmap
Feldman, H., Haas, M., Gandy, S., Schoepp, D. D., Cross, A. J., Mayeux, R. P., Sperling, R. A., Fillit, H. M., van de Hoef, D. L., Dougal, S., et al. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12424 · Cited by 40
Considering a new paradigm for Alzheimer's disease research
Langley, G. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.013 · Cited by 42
Cell-Based Screening: Extracting Meaning from Complex Data
Finkbeiner, S. M., Frumkin, M. A., & Kassner, P. D. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.023 · Cited by 40
Das, D. K., Tapias, V., D’Aiuto, L., Chowdari, K. V., Francis, L., Zhi, Y., Ghosh, A., Surti, U., Tischfield, J. A., Sheldon, M., et al. (2015) · Complex Psychiatry · doi:10.1159/000430916 · Cited by 41
Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease
Inak, G., Lorenz, C., Lisowski, P., Zink, A., Mlody, B., & Prigione, A. (2017) · Stem Cells · doi:10.1002/stem.2637 · Cited by 41
Mechanisms of neuronal survival safeguarded by endocytosis and autophagy
Overhoff, M., Bruyckere, E. D., & Kononenko, N. L. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15194 · Cited by 40
Human iPSC application in Alzheimer’s disease and tau-related neurodegenerative diseases
TCW, J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.043 · Cited by 39
Alzheimer's Disease Modeling: Ups, Downs, and Perspectives for Human Induced Pluripotent Stem Cells
Wojda, U., & Kuźnicki, J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121984 · Cited by 40
The role of the retromer complex in aging-related neurodegeneration: a molecular and genomic review
Reitz, C. (2014) · Molecular Genetics and Genomics · doi:10.1007/s00438-014-0939-9 · Cited by 40
KLF4 N-Terminal Variance Modulates Induced Reprogramming to Pluripotency
Kim, S.-I., Oceguera-Yañez, F., Hirohata, R., Linker, S., Okita, K., Yamada, Y., Yamamoto, T., Yamanaka, S., & Woltjen, K. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.004 · Cited by 39
Weissmiller, A. M., Natera-Naranjo, O., Reyna, S. M., Pearn, M. L., Zhao, X., Nguyen, P. A. H., Cheng, S., Goldstein, L. S. B., Tanzi, R. E., Wagner, S. L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118379 · Cited by 37
Self-citationGurwitz, D. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.3/dgurwitz · Cited by 39
Hoes, M. F., Bömer, N., & van der Meer, P. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0052 · Cited by 43
Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases
Zhang, X., Hu, D., Shang, Y., & Qi, X. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.03.004 · Cited by 36
Tomaskovic‐Crook, E., Gu, Q., Rahim, S. N. A., Wallace, G. G., & Crook, J. M. (2020) · Cells · doi:10.3390/cells9030658 · Cited by 39
Harnessing cerebral organoids for Alzheimer's disease research
Bubnys, A., & Tsai, L. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.10.003 · Cited by 41
Single cell transcriptomic profiling of a neuron-astrocyte assembloid tauopathy model
Rickner, H., Jiang, L., Hong, R., O’Neill, N. K., Mojica, C. A., Snyder, B. J., Zhang, L., Shaw, D., Medalla, M., Wolozin, B. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34005-1 · Cited by 43
Hunsberger, J. G., Efthymiou, A. G., Malik, N., Behl, M., Mead, I., Zeng, X., Simeonov, A. M., & Rao, M. S. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0531 · Cited by 38
Current status of treating neurodegenerative disease with induced pluripotent stem cells
Pen, A. E., & Jensen, U. B. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12545 · Cited by 37
Recent Advances: Decoding Alzheimer’s Disease With Stem Cells
Fang, Y., Gao, T., Zhang, B., & Pu, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00077 · Cited by 39
Li, Y., Sun, X., Liu, H., Huang, L. J., Meng, G., Ding, Y., Su, W., Lu, J., Gong, S., Terstappen, G. C., et al. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00384-7 · Cited by 39
Use of Stem Cell Extracellular Vesicles as a “Holistic” Approach to CNS Repair
Branscome, H., Paul, S., Yin, D., El‐Hage, N., Agbottah, E. T., Zadeh, M. A., Liotta, L. A., & Kashanchi, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00455 · Cited by 37
The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases
Feringa, F. M., Koppes-den Hertog, S. J., Wang, L. Y., Derks, R. J. E., Kruijff, I., Erlebach, L., Heijneman, J., Miramontes, R., Pömpner, N., Blomberg, N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01365-z · Cited by 56
Teli, P., Kale, V. P., & Vaidya, A. (2023) · Cell and Tissue Research · doi:10.1007/s00441-023-03821-2 · Cited by 37
Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling
Beghini, D. G., Kasai-Brunswick, T. H., & Henriques‐Pons, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042392 · Cited by 37
Cell and Gene Therapy in Alzheimer's Disease
Glat, M. J., & Offen, D. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0633 · Cited by 39
Marinho, P. A., Vareschini, D. T., Gomes, I. C. D. S., Paulsen, B. D. S., Furtado, D. R., Castilho, L. R., & Rehen, S. K. (2012) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2012.0141 · Cited by 37
Okada, M., Ikegawa, S., Morioka, M., Yamashita, A., Saito, A., Sawai, H., Murotsuki, J., Ohashi, H., Okamoto, T., Nishimura, G., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu444 · Cited by 37
Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications
Chang, C.-Y., Ting, H.-C., Su, H., & Jeng, J. (2018) · Cell Transplantation · doi:10.1177/0963689718754560 · Cited by 39
Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network
the Dominantly Inherited Alzheimer Network (DIAN), Karch, C. M. M., Hernández, D., Wang, J., Marsh, J. A., Hewitt, A. W., Hsu, S., Norton, J. B., Levitch, D., Donahue, T. A., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0400-0 · Cited by 39
Modelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells
Rowland, H. A., Hooper, N. M., & Kellett, K. A. B. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2663-z · Cited by 38
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 40
Human Induced Pluripotent Stem Cells : Clinical Significance and Applications in Neurologic Diseases
Chang, E.-A., Jin, S.-W., Nam, M., & Kim, S.-D. (2019) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2018.0222 · Cited by 39
Ultrastructural and dynamic studies of the endosomal compartment in Down syndrome
Botté, A., Lainé, J., Xicota, L., Heiligenstein, X., Fontaine, G., Kasri, A., Rivals, I., Goh, P. A., Faklaris, O., Cossec, J., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00956-z · Cited by 35
Human dermal fibroblasts in psychiatry research
Kalman, J. L., Garbett, K. A., Janka, Z., & Mirnics, K. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.067 · Cited by 45
D’Aloia, A., Pastori, V., Blasa, S., Campioni, G., Peri, F., Sacco, E., Ceriani, M., Lecchi, M., & Costa, B. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01790-7 · Cited by 36
Strategies for modeling aging and age-related diseases
Jothi, D., & Kulka, L. A. M. (2024) · npj Aging · doi:10.1038/s41514-024-00161-5 · Cited by 39
Neziri, S., Köseoğlu, A. E., Köseoğlu, G. D., Özgültekin, B., & Özgentürk, N. Ö. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12487 · Cited by 40
Berman, D. E., Ringe, D., Petsko, G. A., & Small, S. A. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0321-y · Cited by 35
Genetic validation of a therapeutic target in a mouse model of ALS
de Boer, A. S., Koszka, K., Kiskinis, E., Suzuki, N., Davis‐Dusenbery, B. N., & Eggan, K. C. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009351 · Cited by 35
Jacquet, A. D. R., Denis, H. L., Cicchetti, F., & Alpaugh, M. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00999-7 · Cited by 36
Cellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 40
Liu, W., Wang, H., Wang, Y., Li, H., & Liu, J. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.102 · Cited by 37
Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery
Tang, S., Xie, M., Cao, N., & Ding, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00789 · Cited by 37
The vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 40
Alzheimer's disease mechanisms in peripheral cells: Promises and challenges
Trushina, E. V. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.008 · Cited by 35
The application of in vitro ‐derived human neurons in neurodegenerative disease modeling
D’Souza, G. X., Rose, S. E., Knupp, A., Nicholson, D. A., Keene, C. D., & Young, J. E. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24615 · Cited by 36
García‐León, J. A., Cáceres-Palomo, L., Sánchez‐Mejías, E., Mejias‐Ortega, M., Nuñez‐Diaz, C., Fernandez-Valenzuela, J. J., Sanchez-Varo, R. M., Dávila, J. C., Vitórica, J., & Gutiérrez, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186867 · Cited by 35
Induced Pluripotent Stem Cell-Based Drug Screening by Use of Artificial Intelligence
Kusumoto, D., Yuasa, S., & Fukuda, K. (2022) · Pharmaceuticals · doi:10.3390/ph15050562 · Cited by 37
Human Pluripotent Stem Cells: Applications and Challenges in Neurological Diseases
Hibaoui, Y., & Féki, A. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00267 · Cited by 35
Choe, M. S., Yeo, H. C., Kim, J., Lee, J., Lee, H. J., Kim, H., Baek, K. M., Jung, N., Choi, M., & Lee, M. Y. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03732-1 · Cited by 39
The role of DNA base excision repair in brain homeostasis and disease
Akbari, M., Morevati, M., Croteau, D. L., & Bohr, V. A. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.029 · Cited by 34
Human induced pluripotent stem cells as a research tool in Alzheimer's disease
Robbins, J. P., & Price, J. (2017) · Psychological Medicine · doi:10.1017/s0033291717002124 · Cited by 34
Ghaffari, L., Starr, A., Nelson, A. T., & Sattler, R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00056 · Cited by 35
Integrated generation of induced pluripotent stem cells in a low-cost device
Lin, H., Li, Q., Du, Q., Wang, O., Wang, Z., Akert, L., Carlson, M. A., Zhang, C., Subramanian, A., Zhang, C., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.027 · Cited by 35
Danter, W. R. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0983-3 · Cited by 35
A microfiber scaffold-based 3D in vitro human neuronal culture model of Alzheimer's disease
Ranjan, V., Qiu, L., Lee, J. W. L., Chen, X., Jang, S. E., Chai, C., Lim, K., Tan, E., Zhang, Y., Huang, W., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm00833h · Cited by 33
Crosstalk between Different DNA Repair Pathways Contributes to Neurodegenerative Diseases
Gupta, S., You, P., SenGupta, T., Nilsen, H. L., & Sharma, K. (2021) · Biology · doi:10.3390/biology10020163 · Cited by 37
Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective
Banerjee, R., Rai, A., Iyer, S., Narwal, S., & Tare, M. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12209 · Cited by 37
APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33
Aversano, S., Caiazza, C., & Caiazzo, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1069482 · Cited by 33
Nanotechnology to Overcome Blood–Brain Barrier Permeability and Damage in Neurodegenerative Diseases
Jiménez, A., Estudillo, E., Guzmán‐Ruiz, M. A., Herrera, N., Victoria-Acosta, G., Cortés-Malagón, E. M., & López-Ornelas, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030281 · Cited by 36
Modeling physiological and pathological human neurogenesis in the dish
Broccoli, V., Giannelli, S. G., & Mazzara, P. G. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00183 · Cited by 35
Pluripotent stem cell-based models of spinal muscular atrophy
Frattini, E., Ruggieri, M., Salani, S., Faravelli, I., Zanetta, C., Nizzardo, M., Simone, C., Magri, F., & Corti, S. P. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.12.005 · Cited by 34
Modelling Alzheimer's disease: Insights fromin vivotoin vitrothree-dimensional culture platforms
Ranjan, V., Qiu, L., Tan, E., Zeng, L., & Zhang, Y. (2018) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2728 · Cited by 41
Pathogenic Tau Causes a Toxic Depletion of Nuclear Calcium
Mahoney, R. E., Ochoa, E., Ramirez, P., Miller, H. E., Beckmann, A., Zuniga, G., Dobrowolski, R., & Frost, B. E. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107900 · Cited by 33
Jacob, F., Schnoll, J. G., Song, H., & Ming, G. (2021) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2020.12.011 · Cited by 34
Mitigating Effect of Estrogen in Alzheimer’s Disease-Mimicking Cerebral Organoid
Kim, J. Y., Mo, H., Kim, J., Kim, J. W., Nam, Y., Rim, Y. A., & Ju, J. H. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.816174 · Cited by 33
Lombino, F. L., Biundo, F., Tamayev, R., Arancio, O., & D'adamio, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057120 · Cited by 33
Verpelli, C., Carlessi, L., Bechi, G., Poli, E., Orellana, D. I., Heise, C., Franceschetti, S., Mantegazza, R., Mantegazza, M., Delia, D., et al. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00175 · Cited by 34
Biswas, M. H. U., Almeida, S., Lopez-Gonzalez, R., Mao, W., Zhang, Z., Karydas, A., Geschwind, M. D., Biernat, J., Mandelkow, E., Futai, K., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.006 · Cited by 33
Alzheimer’s in a dish – induced pluripotent stem cell-based disease modeling
de Leeuw, S., & Tackenberg, C. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0161-0 · Cited by 31
George-Hyslop, F. S., Haneklaus, M., Kivisild, T., & Livesey, F. J. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.03.014 · Cited by 33
iPSCs, aging and age-related diseases
Isobe, K., Cheng, Z., Nishio, N., Thanasegaran, S., Tanaka, Y., & Ito, S. (2014) · New Biotechnology · doi:10.1016/j.nbt.2014.04.004 · Cited by 33
Garate, Z., Davis, B. R., Bustamante, O. Q., & Segovia, J. C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.251 · Cited by 31
Smith, D. K., He, M., Zhang, C., & Zheng, J. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.006 · Cited by 34
Bejoy, J., Song, L., Zhou, Y., & Li, Y. (2017) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0153 · Cited by 32
Recent advances of induced pluripotent stem cells application in neurodegenerative diseases
Amin, N., Tan, X., Ren, Q., Zhu, N., Botchway, B. O. A., Hu, Z., & Fang, M. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109674 · Cited by 36
Heterotypic interactions in amyloid function and disease
Konstantoulea, K., Louros, N. N., Rousseau, F., & Schymkowitz, J. W. H. (2021) · FEBS Journal · doi:10.1111/febs.15719 · Cited by 34
Zollo, A., Allen, Z., Rasmussen, H. F., Iannuzzi, F., Shi, Y., Larsen, A., Maier, T. J., & Matrone, C. (2017) · Neural Plasticity · doi:10.1155/2017/1892612 · Cited by 30
Priming of the Cells: Hypoxic Preconditioning for Stem Cell Therapy.
Wei, Z. Z., Zhu, Y., Zhang, J. Y., McCrary, M. R., Wang, S., Zhang, Y., Yu, S., & Wei, L. (2017) · PubMed Central · doi:10.4103/0366-6999.215324 · Cited by 32
Modeling Neurovascular Disorders and Therapeutic Outcomes with Human-Induced Pluripotent Stem Cells
Bosworth, A. M., Faley, S. L., Bellan, L. M., & Lippmann, E. S. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2017.00087 · Cited by 32
Stem cell models of human synapse development and degeneration
Wilson, E. S., & Litwa, K. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e18-04-0222 · Cited by 30
Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development
Kaffman, A., White, J. D., Wei, L., Johnson, F. K., & Krystal, J. H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_1 · Cited by 28
Phenotypic Screens Targeting Neurodegenerative Diseases
Zhang, M., Luo, G., Zhou, Y., Wang, S., & Zhong, Z. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113499777 · Cited by 31
Nishioka, H., Tooi, N., Isobe, T., Nakatsuji, N., & Aiba, K. (2016) · Scientific Reports · doi:10.1038/srep33427 · Cited by 30
Corrêa-Velloso, J. C., Gonçalves, M. C., Naaldijk, Y., Oliveira‐Giacomelli, Á., Pillat, M. M., & Ulrich, H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.033 · Cited by 31
Yap, M. S., Nathan, K. G., Yeo, Y., Lim, L. W., Poh, C. L., Richards, M., Lim, W. L., Othman, I., & Heng, B. C. (2015) · Stem Cells International · doi:10.1155/2015/105172 · Cited by 31
An update on stem cell biology and engineering for brain development
Parr, C., Yamanaka, S., & Saito, H. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.66 · Cited by 29
Modelling APOE ɛ3/4 allele-associated sporadic Alzheimer’s disease in an induced neuron
Kim, H., Yoo, J., Shin, J., Chang, Y., Jung, J., Jo, D., Kim, J., Jang, W., Lengner, C. J., Kim, B., et al. (2017) · Brain · doi:10.1093/brain/awx144 · Cited by 30
Wang, Y., Liang, G., Liang, S., Mund, R., Shi, Y., & Wei, H. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003224 · Cited by 30
Wu, Q., Karthivashan, G., Nakhaei‐Nejad, M., Anand, B. G., Giuliani, F., & Kar, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.08.148 · Cited by 30
Metadata
- Authors
- Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., Carson, C. T., Laurent, L. C., Marsala, M., Gage, F. H., Remes, A. M., Koo, E. H., & Goldstein, L. S. B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Salk Institute for Biological Studies (US)
- University of California San Diego (US)
- Scripps Research Institute (US)
- BD Biosciences (United States) (US)
- University of Oulu (FI)
- Corresponding author
- Goldstein, Lawrence S. B.
- ORCID
- Venue
- Nature
- Published
- 2012-01-25
- Volume
- 482
- Issue
- 7384
- Pages
- 216-220
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3338985
- OpenAlex
- W2088714934
- Cited by
- 1,253
- References
- 37
- Citations by year
- 2026: 45 · 2025: 55 · 2024: 73 · 2023: 61 · 2022: 100 · 2021: 73 · 2020: 105 · 2019: 86 · 2018: 87 · 2017: 76 · 2016: 108 · 2015: 105 · 2014: 106 · 2013: 95 · 2012: 74
- FWCI
- 81.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- (No Title)
- Funders
- Howard Hughes Medical Institute
- National Institute on Aging (P50AG005131)
- National Institute of General Medical Sciences (T32GM008666)
- National Institute of Neurological Disorders and Stroke (P30NS047101, RC1NS068705)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD001259)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, induced pluripotent stem cells, familial Alzheimer's disease, sporadic Alzheimer's disease, amyloid-beta secretion, gamma-secretase inhibitors, beta-secretase inhibitors, phosphorylated tau, glycogen synthase kinase-3β, APP proteolytic processing, iPSC-derived neurons, patient-derived fibroblasts
- MeSH terms
- Aged, 80 and over, Alzheimer Disease, Astrocytes, Cells, Cultured, Enzyme Activation, Female, Fibroblasts, Humans, Male, Middle Aged, Models, Biological, Neurons, Peptide Fragments, Phosphoproteins, Phosphorylation, Protease Inhibitors, Endosomes, Biomarkers, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Synapsins, tau Proteins, Coculture Techniques, Glycogen Synthase Kinase 3, Amyloid Precursor Protein Secretases, Induced Pluripotent Stem Cells, Proteolysis, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
